| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Hazel L Roberts | Q59691682 |
| P2093 | author name string | David R Brown | |
| P2860 | cites work | Different species of alpha-synuclein oligomers induce calcium influx and seeding. | Q52581429 |
| Mechanism of membrane interaction and disruption by α-synuclein. | Q52617078 | ||
| alpha-Synuclein gene duplication is present in sporadic Parkinson disease. | Q53473267 | ||
| Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease | Q57977634 | ||
| Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers | Q61844539 | ||
| In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies | Q64764806 | ||
| Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies | Q73626218 | ||
| Kinetic measurements give new insights into lipid membrane permeabilization by α-synuclein oligomers | Q82082237 | ||
| Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease | Q42440540 | ||
| ANS binding reveals common features of cytotoxic amyloid species | Q43021800 | ||
| Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. | Q44143951 | ||
| Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function | Q44292891 | ||
| Proteasomal inhibition by alpha-synuclein filaments and oligomers. | Q44719233 | ||
| Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases | Q45072759 | ||
| The many faces of alpha-synuclein mutations | Q45387129 | ||
| Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. | Q45711545 | ||
| Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. | Q45908123 | ||
| Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome | Q46351241 | ||
| Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease | Q46404588 | ||
| Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway | Q46537593 | ||
| Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers | Q46765690 | ||
| Membrane interactions and fibrillization of α-synuclein play an essential role in membrane disruption | Q46807031 | ||
| The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation. | Q46931854 | ||
| Pore-forming proteins share structural and functional homology with amyloid oligomers | Q46968526 | ||
| The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states | Q48155270 | ||
| Oligomeric alpha-synuclein inhibits tubulin polymerization | Q48234434 | ||
| Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. | Q48668545 | ||
| Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers. | Q48806783 | ||
| Lewy body-related alpha-synucleinopathy in the aged human brain. | Q50282783 | ||
| Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models | Q24315670 | ||
| The N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranes | Q24316619 | ||
| α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation | Q24605589 | ||
| Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro | Q24629968 | ||
| α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells | Q24633663 | ||
| Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein | Q24655848 | ||
| Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models | Q24683059 | ||
| Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy | Q24683089 | ||
| α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation | Q26269838 | ||
| Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism | Q27315907 | ||
| Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies | Q27686837 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis | Q29547501 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
| Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. | Q30352615 | ||
| α-Synuclein mutations cluster around a putative protein loop | Q30430404 | ||
| NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease | Q30512262 | ||
| α-Synuclein oligomers impair neuronal microtubule-kinesin interplay. | Q30541822 | ||
| Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants | Q30991616 | ||
| Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy | Q33444800 | ||
| Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models | Q33521022 | ||
| Amyloid-beta-induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy | Q33827991 | ||
| EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. | Q33842865 | ||
| Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia | Q33874305 | ||
| Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs | Q33881676 | ||
| Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. | Q33961445 | ||
| Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. | Q33985326 | ||
| Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity | Q34003885 | ||
| Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. | Q34020622 | ||
| α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer | Q34252869 | ||
| Direct observation of the interconversion of normal and toxic forms of α-synuclein | Q34277399 | ||
| The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease | Q34305509 | ||
| In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells | Q34322594 | ||
| Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. | Q34330786 | ||
| G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome | Q34335126 | ||
| Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast | Q34365610 | ||
| Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α-synuclein oligomers in lipid membranes | Q34374310 | ||
| Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein | Q34517780 | ||
| Effects of curvature and composition on α-synuclein binding to lipid vesicles | Q34590790 | ||
| Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species | Q34624507 | ||
| In vivo demonstration that alpha-synuclein oligomers are toxic | Q34652122 | ||
| Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. | Q34660005 | ||
| Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synuclein | Q34718257 | ||
| Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy | Q34964783 | ||
| The many faces of α-synuclein: from structure and toxicity to therapeutic target | Q34972009 | ||
| Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein | Q35063363 | ||
| Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons | Q35167964 | ||
| Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death | Q35484581 | ||
| Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons | Q35863939 | ||
| Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells | Q36045483 | ||
| Differential activation of the ER stress factor XBP1 by oligomeric assemblies | Q36070065 | ||
| Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology | Q36182604 | ||
| Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo | Q36289970 | ||
| Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure | Q36295920 | ||
| Radiating amyloid fibril formation on the surface of lipid membranes through unit-assembly of oligomeric species of α-synuclein | Q36319183 | ||
| Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. | Q36543608 | ||
| Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein | Q36640417 | ||
| Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking | Q36673364 | ||
| Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain | Q36727241 | ||
| Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy | Q36873680 | ||
| In vitro study of α-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway | Q36939712 | ||
| α-Synuclein and mitochondria: partners in crime? | Q36983221 | ||
| Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element | Q37166339 | ||
| The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding. | Q37246310 | ||
| Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival | Q37347595 | ||
| α-Synuclein misfolding assessed with single molecule AFM force spectroscopy: effect of pathogenic mutations | Q37351690 | ||
| Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation | Q37587111 | ||
| Evidence of native α-synuclein conformers in the human brain | Q37635873 | ||
| Amyloidogenic protein-membrane interactions: mechanistic insight from model systems | Q37771927 | ||
| Α-synuclein misfolding and Parkinson's disease | Q37949158 | ||
| Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease. | Q37981067 | ||
| α-Synuclein and protein degradation systems: a reciprocal relationship | Q38039881 | ||
| α-Synuclein oligomers: an amyloid pore? Insights into mechanisms of α-synuclein oligomer-lipid interactions | Q38041484 | ||
| The function of α-synuclein | Q38139561 | ||
| Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity | Q38180144 | ||
| Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. | Q38734429 | ||
| Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo | Q38966914 | ||
| The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease | Q39080090 | ||
| A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells | Q39545823 | ||
| Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions | Q39610788 | ||
| Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils | Q39632694 | ||
| Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity | Q39742060 | ||
| A causative link between the structure of aberrant protein oligomers and their toxicity. | Q39750915 | ||
| Unique copper-induced oligomers mediate alpha-synuclein toxicity | Q39867665 | ||
| Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein | Q40155070 | ||
| Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. | Q41997706 | ||
| α-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling | Q42184977 | ||
| Redox reactions of the α-synuclein-Cu(2+) complex and their effects on neuronal cell viability | Q42426545 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toxicity | Q274160 |
| neurodegeneration | Q1755122 | ||
| nerve tissue protein | Q6996861 | ||
| Parkinson disease associated proteins | Q77946709 | ||
| Synuclein | Q24767155 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 282-305 | |
| P577 | publication date | 2015-03-25 | |
| P1433 | published in | Biomolecules | Q23929963 |
| P1476 | title | Seeking a mechanism for the toxicity of oligomeric α-synuclein | |
| P478 | volume | 5 |
| Q92563404 | A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging |
| Q42366153 | A study on the modulation of alpha-synuclein fibrillation by Scutellaria pinnatifida extracts and its neuroprotective properties |
| Q35969183 | Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease |
| Q64768798 | Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA) |
| Q57821667 | Alpha-Synuclein Modulates the Physical Properties of DNA |
| Q36336723 | Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease. |
| Q52644596 | Alzheimer's Disease, Oligomers, and Inflammation. |
| Q57804932 | Baseline concentration of misfolded α-synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease |
| Q36373170 | Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. |
| Q64242757 | Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity |
| Q96129239 | Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's diseases |
| Q36107686 | Common structural features of toxic intermediates from α-synuclein and GroES fibrillogenesis detected using cryogenic coherent X-ray diffraction imaging. |
| Q64864824 | Determinants of dopaminergic neuron loss in Parkinson's disease |
| Q26799306 | Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity |
| Q47580972 | Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study |
| Q46308077 | E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation |
| Q51471477 | ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease. |
| Q49939718 | Effect of moxibustion on mTOR-mediated autophagy in rotenone-induced Parkinson's disease model rats. |
| Q37369400 | Environmental and genetic factors support the dissociation between α-synuclein aggregation and toxicity. |
| Q64055149 | Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease |
| Q99617462 | Estimation of Alpha-Synuclein Monomer and Oligomer Levels in the Saliva of the Children With Autism Spectrum Disorder: A Possibility for an Early Diagnosis |
| Q34552244 | Exploring Braak's Hypothesis of Parkinson's Disease. |
| Q64880406 | Extracellular Alpha-Synuclein Oligomers Induce Parkin S-Nitrosylation: Relevance to Sporadic Parkinson's Disease Etiopathology. |
| Q39431937 | Implications of peptide assemblies in amyloid diseases |
| Q37733717 | Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated LRRK2 Gene Mutations |
| Q93051676 | Inorganic polyphosphate, a multifunctional polyanionic protein scaffold |
| Q90167294 | Mechanistic insights into the protective roles of polyphosphate against amyloid cytotoxicity |
| Q92057681 | Misfolded α-synuclein causes hyperactive respiration without functional deficit in live neuroblastoma cells |
| Q58804178 | Model Senescent Microglia Induce Disease Related Changes in α-Synuclein Expression and Activity |
| Q94544629 | Modeling Parkinson's Disease With the Alpha-Synuclein Protein |
| Q49562668 | Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy. |
| Q26771536 | Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation |
| Q64759312 | Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders |
| Q59812935 | New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease |
| Q38794219 | Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. |
| Q91178567 | Partially oxidized DJ-1 inhibits α-synuclein nucleation and remodels mature α-synuclein fibrils in vitro |
| Q42330740 | Polyphosphate: A Conserved Modifier of Amyloidogenic Processes |
| Q37196992 | Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage |
| Q91730805 | Probing the Origin of the Toxicity of Oligomeric Aggregates of α-Synuclein with Antibodies |
| Q39022241 | Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. |
| Q89424515 | Real-time determination of aggregated alpha-synuclein induced membrane disruption at neuroblastoma cells using scanning ion conductance microscopy |
| Q39095738 | Selective neuronal vulnerability in Parkinson disease |
| Q52313428 | Self-administration of methamphetamine alters gut biomarkers of toxicity. |
| Q48342632 | Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α-synuclein |
| Q90189862 | Structure and Aggregation Mechanisms in Amyloids |
| Q38550428 | Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies |
| Q37711589 | Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. |
| Q39148146 | The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease |
| Q39108546 | The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy |
| Q54994816 | The Convergence of Dopamine and α-Synuclein: Implications for Parkinson's Disease. |
| Q46238696 | Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. |
| Q64765285 | Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils |
| Q50919414 | Treadmill Exercise Attenuates α-Synuclein Levels by Promoting Mitochondrial Function and Autophagy Possibly via SIRT1 in the Chronic MPTP/P-Induced Mouse Model of Parkinson's Disease. |
| Q64063434 | Two conformationally distinct α-synuclein oligomers share common epitopes and the ability to impair long-term potentiation |
| Q46252338 | Vertebrate food products as a potential source of prion-like α-synuclein. |
Search more.